Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejo Rodriguez-Vida

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Clinical Genitourinary Cancer|December 18, 2021
Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-AnalysisAlejo Rodriguez-Vida, Andrés Rodríguez-Alonso, Eduardo Useros-Rodríguez, et al.
European Urology Oncology|September 30, 2025
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITANAlejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, et al.
Cancer Medicine|May 22, 2023
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosisLuis P Del Carpio, María Asunción Algarra, Aida Sabaté-Llobera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)Cristina Suárez, James M G Larkin, Poulam Patel, et al.
British Journal of Cancer|October 26, 2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib studyAlejo Rodriguez-Vida, Pablo Maroto, Albert Font, et al.
Molecular Oncology|September 11, 2024
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitorsAnna Hernández-Prat, Alejo Rodriguez-Vida, Laura Cardona, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
Cancer Medicine|December 8, 2023
Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patientsJulián Córdoba Sánchez, Natalia Picola, Alejo Rodriguez-Vida, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 4, 2026
Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter studyTeresa Alonso-Gordoa, Ovidio Fernández-Calvo, Icíar García-Carbonero, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Clinical Genitourinary Cancer|December 18, 2021
Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-AnalysisAlejo Rodriguez-Vida, Andrés Rodríguez-Alonso, Eduardo Useros-Rodríguez, et al.
European Urology Oncology|September 30, 2025
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITANAlejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, et al.
Cancer Medicine|May 22, 2023
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosisLuis P Del Carpio, María Asunción Algarra, Aida Sabaté-Llobera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)Cristina Suárez, James M G Larkin, Poulam Patel, et al.
British Journal of Cancer|October 26, 2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib studyAlejo Rodriguez-Vida, Pablo Maroto, Albert Font, et al.
Molecular Oncology|September 11, 2024
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitorsAnna Hernández-Prat, Alejo Rodriguez-Vida, Laura Cardona, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
Cancer Medicine|December 8, 2023
Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patientsJulián Córdoba Sánchez, Natalia Picola, Alejo Rodriguez-Vida, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 4, 2026
Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter studyTeresa Alonso-Gordoa, Ovidio Fernández-Calvo, Icíar García-Carbonero, et al.
Pageof 9